Table 3.
Medication.
| CMV-positive patients (n = 85) | CMV-negative patients (n = 387) | p value | |
|---|---|---|---|
| Maximum dose of PSL, mean ± SD, mg/day | 552.4 ± 621.1 | 243.3 ± 510.4 | < 0.0001 |
| Cumulative amounts of PSL, mean ± SD, mg | 2785.9 ± 2018.8 | 1330.5 ± 1611.1 | < 0.0001 |
| Intravenous cyclophosphamide, n (%) | 23 (27.1%) | 44 (11.4%) | < 0.0001 |
| Azathioprine, n (%) | 20 (23.5%) | 55 (14.2%) | 0.0053 |
| Tacrolimus, n (%) | 19 (22.4%) | 81 (20.9%) | 0.0977 |
| Methotrexate, n (%) | 13 (15.3%) | 112 (28.9%) | 0.0014 |
| Salazosulfapyridine, n (%) | 8 (9.4%) | 92 (23.8%) | 0.0004 |
| Rituximab, n (%) | 8 (9.4%) | 8 (2.1%) | < 0.0001 |
| Cyclosporine, n (%) | 7 (8.2%) | 14 (3.6%) | 0.0101 |
| Mizoribine, n (%) | 6 (7.1%) | 34 (8.8%) | 0.0858 |
| Bucillamine, n (%) | 3 (3.5%) | 36 (9.3%) | 0.0133 |
| Iguratimod, n (%) | 3 (3.5%) | 14 (3.6%) | 0.1036 |
| Mycophenolate Mofetil, n (%) | 1 (1.2%) | 14 (3.6%) | 0.0409 |
| Sarilumab, n (%) | 1 (1.2%) | 6 (1.6%) | 0.0989 |
| Sodium aurothiomalate, n (%) | 1 (1.2%) | 5 (1.3%) | 0.1032 |
| Baricitinib, n (%) | 1 (1.2%) | 3 (0.8%) | 0.0944 |